Mind Medicine (MindMed) Inc.
MNMD$515M
Small CapNASDAQMedicinal Chemicals & Botanical ProductsBiotechnology🇺🇸North AmericaNEW YORK74 employees
Mind Medicine (MindMed) Inc., doing business as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.
Drugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Nov 2026
Market Overview
Stock performance and key metrics
MNMD News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
MM120 (LSD D-Tartrate)
Generalized Anxiety Disorder
MM-120
ADHD
MM402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA))
Autism Spectrum Disorder
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
MM120 (LSD D-Tartrate) | Phase 3 | Generalized Anxiety Disorder | - | - |
MM-120 | Phase 2 | ADHD | - | - |
MM402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA)) | Phase 2 | Autism Spectrum Disorder | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply